By Brian Shilhavy
Editor – Health Impact News
Cholesterol-lowering statin drugs are a $100 billion-a-year industry.
Lipitor was, by far, the most profitable drug in the history of mankind among all pharmaceutical products, let alone being the most profitable cholesterol drug before its patent expired at the end of 2011. Sales to date from this one particular cholesterol-lowering statin drug have exceeded $140 billion.
Lipitor benefited from the change in marketing laws in 1997 that allowed pharmaceutical companies in the U.S. to advertise their products directly to consumers. Pfizer convinced an entire generation of Americans that they needed a pill to lower their cholesterol in order to prevent heart disease, in what may go down as one of the most brilliant and unethical marketing schemes of all time.
After Lipitor’s patent expired at the end of 2011, the FDA issued its first warnings against statin drugs, which include: liver injury, memory loss, diabetes, and muscle damage, among others. Thousands of lawsuits against the maker of Lipitor followed.
As we have reported many times over the years here at Health Impact News, the cholesterol theory of heart disease is not well-supported by science at all. In fact, much of the science states that cholesterol is an important part of our health, and contrary to popular belief, those with the highest levels of cholesterol actually live longer than those with lower levels of cholesterol in their blood.
However, with such a large segment of the American population moving into their senior years, the pharmaceutical industry’s attempt to keep seniors on cholesterol-lowering statin drugs continues unabated, and the largely pharma-funded corporate media is doing their part to silence doctors and other researchers who criticize the failed cholesterol theory of heart disease.